Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 12 March, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo

Hester Biosciences Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 8, 2025, 1:51 pm

Market Cap 1,217 Cr.
Current Price 1,431
High / Low 3,379/1,293
Stock P/E39.4
Book Value 355
Dividend Yield0.42 %
ROCE9.32 %
ROE6.60 %
Face Value 10.0
PEG Ratio-19.90

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Hester Biosciences Ltd

Competitors of Hester Biosciences Ltd

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
MPS Pharmaa Ltd 6.71 Cr. 3.51 4.33/3.05 0.800.00 %9.15 %34.9 % 10.0
Gujarat Themis Biosyn Ltd 2,663 Cr. 244 390/19250.6 20.50.27 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 53.1 Cr. 71.5 94.9/32.118.0 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 38.0 Cr. 26.0 29.0/8.7438.8 6.640.00 %2.65 %2.08 % 10.0
Godavari Drugs Ltd 70.4 Cr. 93.5 155/79.011.4 55.40.00 %14.4 %15.5 % 10.0
Industry Average17,255.37 Cr1,081.8442.42185.800.37%16.00%16.32%6.27

All Competitor Stocks of Hester Biosciences Ltd

Quarterly Result

MetricDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Sales 56565173756788706779828463
Expenses 41464360565673575763656558
Operating Profit 151071319121413101618195
OPM % 27%18%15%17%25%17%16%19%15%20%21%23%8%
Other Income 3855633625239
Interest 122241382756-4
Depreciation 5555555444444
Profit before tax 121151016897610111213
Tax % 29%20%35%36%24%32%25%40%37%35%29%29%15%
Net Profit 894712674467811
EPS in Rs 9.979.074.678.1613.155.336.904.814.685.827.459.6413.71

Last Updated: February 28, 2025, 7:33 pm

Below is a detailed analysis of the quarterly data for Hester Biosciences Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

  • For Sales, as of Dec 2024, the value is ₹63.00 Cr.. The value appears to be declining and may need further review. It has decreased from 84.00 Cr. (Sep 2024) to ₹63.00 Cr., marking a decrease of 21.00 Cr..
  • For Expenses, as of Dec 2024, the value is ₹58.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 65.00 Cr. (Sep 2024) to ₹58.00 Cr., marking a decrease of 7.00 Cr..
  • For Operating Profit, as of Dec 2024, the value is ₹5.00 Cr.. The value appears to be declining and may need further review. It has decreased from 19.00 Cr. (Sep 2024) to ₹5.00 Cr., marking a decrease of 14.00 Cr..
  • For OPM %, as of Dec 2024, the value is 8.00%. The value appears to be declining and may need further review. It has decreased from 23.00% (Sep 2024) to 8.00%, marking a decrease of 15.00%.
  • For Other Income, as of Dec 2024, the value is ₹9.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Sep 2024) to ₹9.00 Cr., marking an increase of ₹6.00 Cr..
  • For Interest, as of Dec 2024, the value is ₹-4.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 6.00 Cr. (Sep 2024) to ₹-4.00 Cr., marking a decrease of 10.00 Cr..
  • For Depreciation, as of Dec 2024, the value is ₹4.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 4.00 Cr..
  • For Profit before tax, as of Dec 2024, the value is ₹13.00 Cr.. The value appears strong and on an upward trend. It has increased from 12.00 Cr. (Sep 2024) to ₹13.00 Cr., marking an increase of ₹1.00 Cr..
  • For Tax %, as of Dec 2024, the value is 15.00%. The value appears to be improving (decreasing) as expected. It has decreased from 29.00% (Sep 2024) to 15.00%, marking a decrease of 14.00%.
  • For Net Profit, as of Dec 2024, the value is ₹11.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Sep 2024) to ₹11.00 Cr., marking an increase of ₹3.00 Cr..
  • For EPS in Rs, as of Dec 2024, the value is 13.71. The value appears strong and on an upward trend. It has increased from ₹9.64 (Sep 2024) to 13.71, marking an increase of ₹4.07.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 4:05 pm

MetricMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales 656990101123136178183214235266305308
Expenses 434464678289110128146175215251251
Operating Profit 22242534414768556960515458
OPM % 34%36%28%34%33%35%38%30%32%26%19%18%19%
Other Income 01310376114201518
Interest 365444777492014
Depreciation 456671012131317211716
Profit before tax 14131825313657415054403246
Tax % 37%31%26%23%26%36%28%25%31%26%30%34%
Net Profit 991319232341313539282134
EPS in Rs 10.8911.1115.9922.5727.6830.1248.8734.2940.4746.2231.3022.2136.62
Dividend Payout % 18%18%19%18%19%33%23%19%25%22%26%27%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)0.00%44.44%46.15%21.05%0.00%78.26%-24.39%12.90%11.43%-28.21%-25.00%
Change in YoY Net Profit Growth (%)0.00%44.44%1.71%-25.10%-21.05%78.26%-102.65%37.29%-1.47%-39.63%3.21%

Hester Biosciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

No data available for the compounded sales growth chart.

Balance Sheet

Last Updated: January 13, 2025, 3:36 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital 9999999999999
Reserves 59667693113132169193220251271283293
Borrowings 32485559666990121110228274244244
Other Liabilities 24192025253532657374116126123
Total Liabilities 124142160186213244299387411562670662669
Fixed Assets 38546065102110145142133237259240239
CWIP 29213336213277410982149171171
Investments 00000000021253032
Other Assets 5768688589102148170169222237221228
Total Assets 124142160186213244299387411562670662669

Below is a detailed analysis of the balance sheet data for Hester Biosciences Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2024, the value is ₹9.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹9.00 Cr..
  • For Reserves, as of Sep 2024, the value is ₹293.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹283.00 Cr. (Mar 2024) to ₹293.00 Cr., marking an increase of 10.00 Cr..
  • For Borrowings, as of Sep 2024, the value is ₹244.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2024) which recorded ₹244.00 Cr..
  • For Other Liabilities, as of Sep 2024, the value is ₹123.00 Cr.. The value appears to be improving (decreasing). It has decreased from ₹126.00 Cr. (Mar 2024) to ₹123.00 Cr., marking a decrease of 3.00 Cr..
  • For Total Liabilities, as of Sep 2024, the value is ₹669.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹662.00 Cr. (Mar 2024) to ₹669.00 Cr., marking an increase of 7.00 Cr..
  • For Fixed Assets, as of Sep 2024, the value is ₹239.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹240.00 Cr. (Mar 2024) to ₹239.00 Cr., marking a decrease of 1.00 Cr..
  • For CWIP, as of Sep 2024, the value is ₹171.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹171.00 Cr..
  • For Investments, as of Sep 2024, the value is ₹32.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹30.00 Cr. (Mar 2024) to ₹32.00 Cr., marking an increase of 2.00 Cr..
  • For Other Assets, as of Sep 2024, the value is ₹228.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹221.00 Cr. (Mar 2024) to ₹228.00 Cr., marking an increase of 7.00 Cr..
  • For Total Assets, as of Sep 2024, the value is ₹669.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹662.00 Cr. (Mar 2024) to ₹669.00 Cr., marking an increase of 7.00 Cr..

Notably, the Reserves (₹293.00 Cr.) exceed the Borrowings (244.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +1292019353847375892448
Cash from Investing Activity +-23-15-21-13-30-26-21-73-42-117-77-22
Cash from Financing Activity +1077-72-11319-1811242-26
Net Cash Flow-125-16128-17-23-12-0

Free Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow-10.00-24.00-30.00-25.00-25.00-22.00-22.00-66.00-41.00-168.00-223.00-190.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days85757295798767116848610994
Inventory Days7361,145431627376505540834452424399288
Days Payable135145681098410093261204101141101
Cash Conversion Cycle6851,074434614371491514690332409367281
Working Capital Days137194158188145150153169172204203181
ROCE %20%18%15%19%19%20%26%16%18%14%9%9%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Promoters53.73%53.73%53.73%53.73%53.73%53.73%53.73%53.73%53.73%53.73%53.73%53.73%
FIIs0.92%0.72%0.62%0.45%0.45%0.45%0.42%0.43%0.43%0.52%0.61%0.59%
DIIs0.03%0.04%0.03%0.03%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.02%
Public45.31%45.51%45.60%45.77%45.81%45.82%45.84%45.83%45.84%45.74%45.66%45.65%
No. of Shareholders15,01713,43913,71113,39113,12012,98413,34213,45012,84411,30511,53811,473

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Motilal Oswal S&P BSE Healthcare ETF410.080.01412025-03-060%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 24.8832.9646.4140.7936.44
Diluted EPS (Rs.) 24.8832.9646.4140.7936.44
Cash EPS (Rs.) 39.6552.1065.4156.4451.81
Book Value[Excl.RevalReserv]/Share (Rs.) 356.03339.19314.32277.37242.73
Book Value[Incl.RevalReserv]/Share (Rs.) 356.03339.19314.32277.37242.73
Revenue From Operations / Share (Rs.) 357.99312.79276.25251.95215.43
PBDIT / Share (Rs.) 75.5877.3086.6686.2172.61
PBIT / Share (Rs.) 55.3952.9767.1770.5657.24
PBT / Share (Rs.) 32.1442.0262.3958.9048.58
Net Profit / Share (Rs.) 19.4627.7745.9240.7936.44
NP After MI And SOA / Share (Rs.) 22.2031.3046.4140.4734.29
PBDIT Margin (%) 21.1124.7131.3734.2133.70
PBIT Margin (%) 15.4716.9324.3128.0026.57
PBT Margin (%) 8.9713.4322.5823.3722.54
Net Profit Margin (%) 5.438.8716.6216.1816.91
NP After MI And SOA Margin (%) 6.2010.0016.8016.0615.91
Return on Networth / Equity (%) 6.479.5115.1815.0814.50
Return on Capital Employeed (%) 8.468.6412.2817.1616.06
Return On Assets (%) 2.853.977.028.377.54
Long Term Debt / Equity (X) 0.620.660.630.360.38
Total Debt / Equity (X) 0.810.950.850.370.54
Asset Turnover Ratio (%) 0.450.430.520.620.58
Current Ratio (X) 2.031.532.012.631.91
Quick Ratio (X) 1.310.961.231.621.14
Inventory Turnover Ratio (X) 0.670.660.520.390.49
Dividend Payout Ratio (NP) (%) 36.0231.9421.5416.3020.41
Dividend Payout Ratio (CP) (%) 18.8617.9715.1711.7614.09
Earning Retention Ratio (%) 63.9868.0678.4683.7079.59
Cash Earning Retention Ratio (%) 81.1482.0384.8388.2485.91
Interest Coverage Ratio (X) 3.257.0618.1411.118.38
Interest Coverage Ratio (Post Tax) (X) 1.843.5310.616.765.21
Enterprise Value (Cr.) 1416.651555.602514.681703.08877.85
EV / Net Operating Revenue (X) 4.655.8510.707.954.79
EV / EBITDA (X) 22.0323.6634.1123.2214.21
MarketCap / Net Operating Revenue (X) 3.884.869.837.614.29
Retention Ratios (%) 63.9768.0578.4583.6979.58
Price / BV (X) 4.054.628.887.143.91
Price / Net Operating Revenue (X) 3.884.869.837.614.29
EarningsYield 0.010.020.010.020.03

After reviewing the key financial ratios for Hester Biosciences Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
  • For Basic EPS (Rs.), as of Mar 24, the value is 24.88. This value is within the healthy range. It has decreased from 32.96 (Mar 23) to 24.88, marking a decrease of 8.08.
  • For Diluted EPS (Rs.), as of Mar 24, the value is 24.88. This value is within the healthy range. It has decreased from 32.96 (Mar 23) to 24.88, marking a decrease of 8.08.
  • For Cash EPS (Rs.), as of Mar 24, the value is 39.65. This value is within the healthy range. It has decreased from 52.10 (Mar 23) to 39.65, marking a decrease of 12.45.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 356.03. It has increased from 339.19 (Mar 23) to 356.03, marking an increase of 16.84.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 356.03. It has increased from 339.19 (Mar 23) to 356.03, marking an increase of 16.84.
  • For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 357.99. It has increased from 312.79 (Mar 23) to 357.99, marking an increase of 45.20.
  • For PBDIT / Share (Rs.), as of Mar 24, the value is 75.58. This value is within the healthy range. It has decreased from 77.30 (Mar 23) to 75.58, marking a decrease of 1.72.
  • For PBIT / Share (Rs.), as of Mar 24, the value is 55.39. This value is within the healthy range. It has increased from 52.97 (Mar 23) to 55.39, marking an increase of 2.42.
  • For PBT / Share (Rs.), as of Mar 24, the value is 32.14. This value is within the healthy range. It has decreased from 42.02 (Mar 23) to 32.14, marking a decrease of 9.88.
  • For Net Profit / Share (Rs.), as of Mar 24, the value is 19.46. This value is within the healthy range. It has decreased from 27.77 (Mar 23) to 19.46, marking a decrease of 8.31.
  • For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 22.20. This value is within the healthy range. It has decreased from 31.30 (Mar 23) to 22.20, marking a decrease of 9.10.
  • For PBDIT Margin (%), as of Mar 24, the value is 21.11. This value is within the healthy range. It has decreased from 24.71 (Mar 23) to 21.11, marking a decrease of 3.60.
  • For PBIT Margin (%), as of Mar 24, the value is 15.47. This value is within the healthy range. It has decreased from 16.93 (Mar 23) to 15.47, marking a decrease of 1.46.
  • For PBT Margin (%), as of Mar 24, the value is 8.97. This value is below the healthy minimum of 10. It has decreased from 13.43 (Mar 23) to 8.97, marking a decrease of 4.46.
  • For Net Profit Margin (%), as of Mar 24, the value is 5.43. This value is within the healthy range. It has decreased from 8.87 (Mar 23) to 5.43, marking a decrease of 3.44.
  • For NP After MI And SOA Margin (%), as of Mar 24, the value is 6.20. This value is below the healthy minimum of 8. It has decreased from 10.00 (Mar 23) to 6.20, marking a decrease of 3.80.
  • For Return on Networth / Equity (%), as of Mar 24, the value is 6.47. This value is below the healthy minimum of 15. It has decreased from 9.51 (Mar 23) to 6.47, marking a decrease of 3.04.
  • For Return on Capital Employeed (%), as of Mar 24, the value is 8.46. This value is below the healthy minimum of 10. It has decreased from 8.64 (Mar 23) to 8.46, marking a decrease of 0.18.
  • For Return On Assets (%), as of Mar 24, the value is 2.85. This value is below the healthy minimum of 5. It has decreased from 3.97 (Mar 23) to 2.85, marking a decrease of 1.12.
  • For Long Term Debt / Equity (X), as of Mar 24, the value is 0.62. This value is within the healthy range. It has decreased from 0.66 (Mar 23) to 0.62, marking a decrease of 0.04.
  • For Total Debt / Equity (X), as of Mar 24, the value is 0.81. This value is within the healthy range. It has decreased from 0.95 (Mar 23) to 0.81, marking a decrease of 0.14.
  • For Asset Turnover Ratio (%), as of Mar 24, the value is 0.45. It has increased from 0.43 (Mar 23) to 0.45, marking an increase of 0.02.
  • For Current Ratio (X), as of Mar 24, the value is 2.03. This value is within the healthy range. It has increased from 1.53 (Mar 23) to 2.03, marking an increase of 0.50.
  • For Quick Ratio (X), as of Mar 24, the value is 1.31. This value is within the healthy range. It has increased from 0.96 (Mar 23) to 1.31, marking an increase of 0.35.
  • For Inventory Turnover Ratio (X), as of Mar 24, the value is 0.67. This value is below the healthy minimum of 4. It has increased from 0.66 (Mar 23) to 0.67, marking an increase of 0.01.
  • For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 36.02. This value is within the healthy range. It has increased from 31.94 (Mar 23) to 36.02, marking an increase of 4.08.
  • For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 18.86. This value is below the healthy minimum of 20. It has increased from 17.97 (Mar 23) to 18.86, marking an increase of 0.89.
  • For Earning Retention Ratio (%), as of Mar 24, the value is 63.98. This value is within the healthy range. It has decreased from 68.06 (Mar 23) to 63.98, marking a decrease of 4.08.
  • For Cash Earning Retention Ratio (%), as of Mar 24, the value is 81.14. This value exceeds the healthy maximum of 70. It has decreased from 82.03 (Mar 23) to 81.14, marking a decrease of 0.89.
  • For Interest Coverage Ratio (X), as of Mar 24, the value is 3.25. This value is within the healthy range. It has decreased from 7.06 (Mar 23) to 3.25, marking a decrease of 3.81.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 1.84. This value is below the healthy minimum of 3. It has decreased from 3.53 (Mar 23) to 1.84, marking a decrease of 1.69.
  • For Enterprise Value (Cr.), as of Mar 24, the value is 1,416.65. It has decreased from 1,555.60 (Mar 23) to 1,416.65, marking a decrease of 138.95.
  • For EV / Net Operating Revenue (X), as of Mar 24, the value is 4.65. This value exceeds the healthy maximum of 3. It has decreased from 5.85 (Mar 23) to 4.65, marking a decrease of 1.20.
  • For EV / EBITDA (X), as of Mar 24, the value is 22.03. This value exceeds the healthy maximum of 15. It has decreased from 23.66 (Mar 23) to 22.03, marking a decrease of 1.63.
  • For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 3.88. This value exceeds the healthy maximum of 3. It has decreased from 4.86 (Mar 23) to 3.88, marking a decrease of 0.98.
  • For Retention Ratios (%), as of Mar 24, the value is 63.97. This value is within the healthy range. It has decreased from 68.05 (Mar 23) to 63.97, marking a decrease of 4.08.
  • For Price / BV (X), as of Mar 24, the value is 4.05. This value exceeds the healthy maximum of 3. It has decreased from 4.62 (Mar 23) to 4.05, marking a decrease of 0.57.
  • For Price / Net Operating Revenue (X), as of Mar 24, the value is 3.88. This value exceeds the healthy maximum of 3. It has decreased from 4.86 (Mar 23) to 3.88, marking a decrease of 0.98.
  • For EarningsYield, as of Mar 24, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 23) to 0.01, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Hester Biosciences Ltd as of March 12, 2025 is: ₹741.62

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 12, 2025, Hester Biosciences Ltd is Overvalued by 48.17% compared to the current share price 1,431.00

Intrinsic Value of Hester Biosciences Ltd as of March 12, 2025 is: 726.94

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 12, 2025, Hester Biosciences Ltd is Overvalued by 49.20% compared to the current share price 1,431.00

Last 5 Year EPS CAGR: -1.98%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 16.92%, which is a positive sign.
  2. The company has higher reserves (170.69 cr) compared to borrowings (126.15 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (174.85 cr) and profit (35.15 cr) over the years.
  1. The stock has a high average Working Capital Days of 171.17, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 432.42, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Hester Biosciences Ltd:
    1. Net Profit Margin: 5.43%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 8.46% (Industry Average ROCE: 16%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 6.47% (Industry Average ROE: 16.32%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 1.84
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.31
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 39.4 (Industry average Stock P/E: 42.42)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.81
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Hester Biosciences Ltd. is a Public Limited Listed company incorporated on 29/04/1987 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L99999GJ1987PLC022333 and registration number is 022333. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 285.16 Cr. and Equity Capital is Rs. 8.51 Cr. for the Year ended 31/03/2024.
INDUSTRYADDRESSCONTACT
Pharmaceuticals�Pushpak� 1st Floor, Panchvati Circle, Ahmedabad Gujarat 380006mail@hester.in
http://www.hester.in
Management
NamePosition Held
Dr. Bhupendra GandhiChairman
Mr. Rajiv GandhiManaging Director & CEO
Ms. Priya GandhiExecutive Director
Mr. Ravin GandhiDirector
Mr. Sanjiv GandhiDirector
Mr. Ashok BhadakalIndependent Director
Ms. Sandhya PatelIndependent Director
Mr. Ameet DesaiIndependent Director
Mr. Anil JainIndependent Director
Mr. Jatin TrivediIndependent Director
Ms. Nina GandhiAlternate Director

FAQ

What is the latest intrinsic value of Hester Biosciences Ltd?

The latest intrinsic value of Hester Biosciences Ltd as on 12 March 2025 is ₹741.62, which is 48.17% lower than the current market price of 1,431.00, indicating the stock is overvalued by 48.17%. The intrinsic value of Hester Biosciences Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹1,217 Cr. and recorded a high/low of ₹3,379/1,293 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹293 Cr and total liabilities of ₹669 Cr.

What is the Market Cap of Hester Biosciences Ltd?

The Market Cap of Hester Biosciences Ltd is 1,217 Cr..

What is the current Stock Price of Hester Biosciences Ltd as on 12 March 2025?

The current stock price of Hester Biosciences Ltd as on 12 March 2025 is ₹1,431.

What is the High / Low of Hester Biosciences Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Hester Biosciences Ltd stocks is ₹3,379/1,293.

What is the Stock P/E of Hester Biosciences Ltd?

The Stock P/E of Hester Biosciences Ltd is 39.4.

What is the Book Value of Hester Biosciences Ltd?

The Book Value of Hester Biosciences Ltd is 355.

What is the Dividend Yield of Hester Biosciences Ltd?

The Dividend Yield of Hester Biosciences Ltd is 0.42 %.

What is the ROCE of Hester Biosciences Ltd?

The ROCE of Hester Biosciences Ltd is 9.32 %.

What is the ROE of Hester Biosciences Ltd?

The ROE of Hester Biosciences Ltd is 6.60 %.

What is the Face Value of Hester Biosciences Ltd?

The Face Value of Hester Biosciences Ltd is 10.0.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Hester Biosciences Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE